Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
JHPCYDrugs in Pipeline
23
Phase 3 Programs
13
Upcoming Catalysts
1
Next Catalyst
May 15, 2026
9wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
HR17031 injection
Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
SHR-1209
Primary Hypercholesterolemia
apatinib
Non-Small-Cell Lung Cancer
SHR6390
Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
Hetrombopag Olamine
Severe Aplastic Anemia
SHR0302
Rheumatoid Arthritis
Hetrombopag
Chemotherapy-Induced Thrombocytopenia
Remimazolam Tosilate
General Anesthesia
Propofol
Anesthesia for Elective Surgery Patients
VC005 tablets
Active Ankylosing Spondylitis
SHR7280 tablets
Uterine Fibroids With Menorrhagia
SHR-A1811
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Pyrotinib
HER2-positive Breast Cancer
FRSW117
Severe Hemophilia A
HRS-4508 tablet
Lung Cancer
Famitinib
Colorectal Cancer
SHR-3167
Type 2 Diabetes Mellitus
HR19042 Capsules
IgA Nephropathy
SHR-1210
Nasopharyngeal Carcinoma
HS-20093 for Injection
Prostate Cancer
AZD4205
Nonsmall Cell Lung Cancer
SHR-A1811 Injection
Recurrent or Metastatic Cervical Cancer
KN046
Esophageal Squamous Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HR17031 injection | Phase 3 | Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs | - | - |
SHR-1209 | Phase 3 | Primary Hypercholesterolemia | - | - |
apatinib | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
SHR6390 | Phase 3 | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer | - | - |
Hetrombopag Olamine | Phase 3 | Severe Aplastic Anemia | - | - |
SHR0302 | Phase 3 | Rheumatoid Arthritis | - | - |
Hetrombopag | Phase 3 | Chemotherapy-Induced Thrombocytopenia | - | - |
Remimazolam Tosilate | Phase 3 | General Anesthesia | - | - |
Propofol | Phase 3 | Anesthesia for Elective Surgery Patients | - | - |
VC005 tablets | Phase 3 | Active Ankylosing Spondylitis | - | - |
SHR7280 tablets | Phase 3 | Uterine Fibroids With Menorrhagia | - | - |
SHR-A1811 | Phase 3 | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | - | - |
Pyrotinib | Phase 3 | HER2-positive Breast Cancer | - | - |
FRSW117 | Phase 2 | Severe Hemophilia A | - | - |
HRS-4508 tablet | Phase 2 | Lung Cancer | - | - |
Famitinib | Phase 2 | Colorectal Cancer | - | - |
SHR-3167 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
HR19042 Capsules | Phase 2 | IgA Nephropathy | - | - |
SHR-1210 | Phase 2 | Nasopharyngeal Carcinoma | - | - |
HS-20093 for Injection | Phase 2 | Prostate Cancer | - | - |
AZD4205 | Phase 2 | Nonsmall Cell Lung Cancer | - | - |
SHR-A1811 Injection | Phase 2 | Recurrent or Metastatic Cervical Cancer | - | - |
KN046 | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |